Cannabis Chewing Gum for Multiple Sclerosis in Development
AXIM Biotechnologies and its partner Quay Pharmaceuticals have obtained the necessary licenses to move forward with the development of a cannabis chewing gum, called MedChew Rx, for the treatment of multiple sclerosis (MS).
MedChew Rx is being developed as a pharmaceutical drug to treat pain and spasticity associated with MS, according to a press release.
The gum consists of 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC).
Read More at SpecialtyPharmacyTimes.com